CALR and essential thrombocythemia: Surprisingly, although CALR and JAK2V617F mutations act on the same intracellular signaling pathways, the thrombotic risk is significantly lower in patients carrying CALR mutations compared with JAK2V617F in essential thrombocythemia (ET) [1,11].